Pharma Pulse 6/19/24: How AI is Revolutionizing Drug Development, Coverage from DIA 2024 & more
The latest news for pharma industry insiders.
DIA 2024: Machine Learning and Simulations to Facilitate Clinical Trials
In a session at the 2024 DIA Global Annual meeting in San Diego, CA, Raviv Pryluk, CEO & co-founder, PhaseV; Sam Miller, head of strategic consulting, Exploristics; and Andrew Stelzer, head of business development, Unlearn.ai addressed a number of ways simulations are currently being utilized in clinical research.
Young Adults with Type 1 Diabetes Have Suboptimal Glucose Control
Researchers suggest younger people with diabetes need more education and better support to manage their diabetes.
Establishing a Data Ecosystem Using Automation to Optimize Regulatory-Compliant Clinical Trials
Significant advances in technology are providing new opportunities to collect and utilize real-world data to establish better clinical trial protocols that have a patient-centric focus and the ability to transform healthcare. However, it is important to understand how such applications work and their impact on safety.
This webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance.
How A.I. Is Revolutionizing Drug Development
In high-tech labs, workers are generating data to train A.I. algorithms to design better medicine, faster. But the transformation is just getting underway.
A new study “Self-administered gerocognitive examination (SAGE) aids early detection of cognitive impairment at primary care provider visits” published today in Frontier in Medicine by researchers at The Ohio State University Wexner Medical Center finds that the practical and brief SAGE test was easily incorporated into primary care providers’ visits. This screening tool resulted in a significant increase in the detection of cognitive concerns.
Silence Therapeutics plc on LinkedIn
Discover how Craig Tooman, President and CEO, navigated the #biotechsector's post-pandemic funding challenges to strengthen Silence’s position in the #siRNAdrug field in this interview with Pharmaceutical Executive : https://bit.ly/45r9zOF
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
